#ATAI↓

ATAI/ 10/24/2025 · 6:01 AM

Berenberg Rates ATAI Life Sciences Buy with $12 Target on Strong Pipeline

Berenberg maintains Buy rating on ATAI Life Sciences (ATAI) with $12 price target, citing exceptional progress, strong pipeline momentum, and upcoming Phase 3 trials for psychedelic treatments.

ATAI/ 10/17/2025 · 1:28 PM

Jefferies Boosts Atai Life Sciences Price Target to $10 on FDA Breakthrough Win

Jefferies raises Atai Life Sciences price target to $10 following FDA Breakthrough Therapy Designation for depression drug BPL-003, citing 72% approval rate for BTD drugs.

ATAI/ 10/13/2025 · 6:16 AM

Needham Sees Major Upside in Atai Life Sciences' Depression Treatment

Needham initiates Atai Life Sciences with Buy rating and $12 target, projecting BPL-003 could capture 20% market share by 2035 with $2.5B+ in sales.